JMP Securities lowered the firm’s price target on OptimizeRx (OPRX) to $8 from $16 and keeps an Outperform rating on the shares.
JMP Securities raised the firm’s price target on Dave (DAVE) to $115 from $75 and keeps an Outperform rating on the shares. Dave’s ...